OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+60.43%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$242M
AUM Growth
+$242M
(+9.1%)
Cap. Flow
-$10.2M
Cap. Flow
% of AUM
-4.21%
Top 10 Holdings %
Top 10 Hldgs %
67.89%
Holding
53
New
6
Increased
20
Reduced
10
Closed
11
Top Buys
| 1 |
Rhythm Pharmaceuticals
RYTM
|
$11M |
| 2 |
TELA Bio
TELA
|
$3.35M |
| 3 |
Larimar Therapeutics
LRMR
|
$2.33M |
| 4 |
Ocular Therapeutix
OCUL
|
$2.03M |
| 5 |
Edgewise Therapeutics
EWTX
|
$1.81M |
Top Sells
| 1 |
Kiniksa Pharmaceuticals
KNSA
|
$7.89M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$5.58M |
| 3 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$5.34M |
| 4 |
908 Devices
MASS
|
$3.43M |
| 5 |
Celldex Therapeutics
CLDX
|
$2.43M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Ginkgo Bioworks
DNA
$671M
| – | – |
-815,000
| Closed | -$1.94M |
|
|
52
Celldex Therapeutics
CLDX
$1.57B
| – | – |
-90,000
| Closed | -$2.43M |
|
53
Avalo Therapeutics
AVTX
$139M
| – | – |
-450,000
| Closed | -$225K |
|